Amgen expects Xgeva CRPC bone metastases decision by April
This article was originally published in Scrip
Executive Summary
Amgen's RANK ligand inhibitor denosumab could have another indication under its belt by next spring if the US FDA approves the bone-targeted drug by its newly assigned 26 April Prescription Drug User Fee Act (PDUFA) action date as a therapy to reduce the risk of developing bone metastases in men with castrate-resistant prostate cancer (CRPC).